Traumatic brain injury and trichloroethylene exposure interact and produce functional, histological, and mitochondrial deficits

Experimental Neurology

Volumn 234, Issue 1, 2012, Pages 85-94

  Sauerbeck, Andrew ^a   Hunter, Randy ^a   Bing, Guoying ^a   Sullivan, Patrick G ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

Author keywords

Dual injury; Mitochondria; Multifactorial; Parkinson's disease; Synergy; Traumatic brain injury; Trichloroethylene

Indexed keywords

DOPAMINE 2 RECEPTOR; TRICHLOROETHYLENE; TYROSINE 3 MONOOXYGENASE;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN CORTEX; BRAIN NERVE CELL; CELL DEATH; CONTROLLED STUDY; CORPUS STRIATUM; DISEASE ASSOCIATION; DISEASE SEVERITY; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DOPAMINERGIC NERVE CELL; MALE; MOTOR DYSFUNCTION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RAT; ROTAROD TEST; SUBSTANTIA NIGRA; TRAUMATIC BRAIN INJURY;

ANIMALS; BRAIN INJURIES; CORPUS STRIATUM; DISEASE MODELS, ANIMAL; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; GENE EXPRESSION REGULATION; MALE; MITOCHONDRIAL DISEASES; MOTOR ACTIVITY; MOVEMENT DISORDERS; OXYGEN CONSUMPTION; RATS; RATS, INBRED F344; RECEPTORS, DOPAMINE D2; ROTAROD PERFORMANCE TEST; SOLVENTS; TRICHLOROETHYLENE; TYROSINE 3-MONOOXYGENASE;

EID: 84857500330     PISSN: 00144886     EISSN: 10902430     Source Type: Journal    
DOI: 10.1016/j.expneurol.2011.12.012     Document Type: Article

References (62)

1. Afonso-Oramas D., Cruz-Muros I., Alvarez de la Rosa D., Abreu P., Giraldez T., Castro-Hernandez J., Salas-Hernandez J., Lanciego J.L., Rodriguez M., Gonzalez-Hernandez T. Dopamine transporter glycosylation correlates with the vulnerability of midbrain dopaminergic cells in Parkinson's disease. Neurobiol. Dis. 2009, 36:494-508.
2. Akundi R.S., Macho A., Munoz E., Lieb K., Bringmann G., Clement H.W., Hull M., Fiebich B.L. 1-trichloromethyl-1,2,3,4-tetrahydro-beta-carboline-induced apoptosis in the human neuroblastoma cell line SK-N-SH. J. Neurochem. 2004, 91:263-273.
3. Arundine M., Chopra G.K., Wrong A., Lei S., Aarts M.M., MacDonald J.F., Tymianski M. Enhanced vulnerability to NMDA toxicity in sublethal traumatic neuronal injury in vitro. J. Neurotrauma 2003, 20:1377-1395.
4. Arundine M., Aarts M., Lau A., Tymianski M. Vulnerability of central neurons to secondary insults after in vitro mechanical stretch. J. Neurosci. 2004, 24:8106-8123.
5. ATSDR Toxicological Profile for Trichloroethylene 1997, U.S. Department of Health and Human Services.
6. Bakke B., Stewart P.A., Waters M.A. Uses of and exposure to trichloroethylene in U.S. industry: a systematic literature review. J. Occup. Environ. Hyg. 2007, 4:375-390.
7. Bales J.W., Yan H.Q., Ma X., Li Y., Samarasinghe R., Dixon C.E. The dopamine and cAMP regulated phosphoprotein, 32kDa (DARPP-32) signaling pathway: a novel therapeutic target in traumatic brain injury. Exp. Neurol. 2011, 229:300-307.
8. Bender A., Krishnan K.J., Morris C.M., Taylor G.A., Reeve A.K., Perry R.H., Jaros E., Hersheson J.S., Betts J., Klopstock T., Taylor R.W., Turnbull D.M. High levels of mitochondrial DNA deletions in substantia nigra neurons in aging and Parkinson disease. Nat. Genet. 2006, 38:515-517.
9. Bower J.H., Maraganore D.M., Peterson B.J., McDonnell S.K., Ahlskog J.E., Rocca W.A. Head trauma preceding PD: a case-control study. Neurology 2003, 60:1610-1615.
10. Bringmann G., God R., Feineis D., Janetzky B., Reichmann H. TaClo as a neurotoxic lead: improved synthesis, stereochemical analysis, and inhibition of the mitochondrial respiratory chain. J. Neural Transm. 1995, 46:245-254.
11. Bringmann G., God R., Feineis D., Wesemann W., Riederer P., Rausch W.D., Reichmann H., Sontag K.H. The TaClo concept: 1-trichloromethyl-1,2,3,4-tetrahydro-beta-carboline (TaClo), a new toxin for dopaminergic neurons. J. Neural Transm. 1995, 46:235-244.
12. Brown R.C., Lockwood A.H., Sonawane B.R. Neurodegenerative diseases: an overview of environmental risk factors. Environ. Health Perspect. 2005, 113:1250-1256.
13. Doder M., Jahanshahi M., Turjanski N., Moseley I.F., Lees A.J. Parkinson's syndrome after closed head injury: a single case report. J. Neurol. Neurosurg. Psychiatry 1999, 66:380-385.
14. Donnemiller E., Brenneis C., Wissel J., Scherfler C., Poewe W., Riccabona G., Wenning G.K. Impaired dopaminergic neurotransmission in patients with traumatic brain injury: a SPECT study using 123I-beta-CIT and 123I-IBZM. Eur. J. Nucl. Med. 2000, 27:1410-1414.
15. EOHS Encyclopedia of Occupational Health and Saftey 4th Edition, 1998. International Labour Office.
16. Factor S.A., Weiner W.J. Prior history of head trauma in Parkinson's disease. Mov. Disord. 1991, 6:225-229.
17. Factor S.A., Sanchez-Ramos J., Weiner W.J. Trauma as an etiology of parkinsonism: a historical review of the concept. Mov. Disord. 1988, 3:30-36.
18. Fei Q., Ethell D.W. Maneb potentiates paraquat neurotoxicity by inducing key Bcl-2 family members. J. Neurochem. 2008, 105:2091-2097.
19. Ferrante R.J., Schulz J.B., Kowall N.W., Beal M.F. Systemic administration of rotenone produces selective damage in the striatum and globus pallidus, but not in the substantia nigra. Brain Res. 1997, 753:157-162.
20. Gash D.M., Rutland K., Hudson N.L., Sullivan P.G., Bing G., Cass W.A., Pandya J.D., Liu M., Choi D.Y., Hunter R.L., Gerhardt G.A., Smith C.D., Slevin J.T., Prince T.S. Trichloroethylene: Parkinsonism and complex 1 mitochondrial neurotoxicity. Ann. Neurol. 2008, 63:184-192.
21. Hallam T.M., Floyd C.L., Folkerts M.M., Lee L.L., Gong Q.Z., Lyeth B.G., Muizelaar J.P., Berman R.F. Comparison of behavioral deficits and acute neuronal degeneration in rat lateral fluid percussion and weight-drop brain injury models. J. Neurotrauma 2004, 21:521-539.
22. Hutson C.B., Lazo C.R., Mortazavi F., Giza C.C., Hovda D., Chesselet M.F. Traumatic brain injury in adult rats causes progressive nigrostriatal dopaminergic cell loss and enhanced vulnerability to the pesticide paraquat. J. Neurotrauma 2011, 28:1783-1801.
23. Janetzky B., God R., Bringmann G., Reichmann H. 1-Trichloromethyl-1,2,3,4-tetrahydro-beta-carboline, a new inhibitor of complex I. J. Neural Transm. 1995, 46:265-273.
24. Kilburn K.H. Is neurotoxicity associated with environmental trichloroethylene (TCE)?. Arch. Environ. Health 2002, 57:113-120.
25. Kochen W., Kohlmuller D., De Biasi P., Ramsay R. The endogeneous formation of highly chlorinated tetrahydro-beta-carbolines as a possible causative mechanism in idiopathic Parkinson's disease. Adv. Exp. Med. Biol. 2003, 527:253-263.
26. Koutouzis T.K., Borlongan C.V., Scorcia T., Creese I., Cahill D.W., Freeman T.B., Sanberg P.R. Systemic 3-nitropropionic acid: long-term effects on locomotor behavior. Brain Res. 1994, 646:242-246.
27. Landrigan P.J., Sonawane B., Butler R.N., Trasande L., Callan R., Droller D. Early environmental origins of neurodegenerative disease in later life. Environ. Health Perspect. 2005, 113:1230-1233.
28. Langston J.W., Ballard P.A. Parkinson's disease in a chemist working with 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine. N. Engl. J. Med. 1983, 309:310.
29. Langston J.W., Ballard P., Tetrud J.W., Irwin I. Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science 1983, 219:979-980.
30. Lifshitz J., Sullivan P.G., Hovda D.A., Wieloch T., McIntosh T.K. Mitochondrial damage and dysfunction in traumatic brain injury. Mitochondrion 2004, 4:705-713.
31. Ling Z.D., Chang Q., Lipton J.W., Tong C.W., Landers T.M., Carvey P.M. Combined toxicity of prenatal bacterial endotoxin exposure and postnatal 6-hydroxydopamine in the adult rat midbrain. Neuroscience 2004, 124:619-628.
32. Ling Z., Zhu Y., Tong C., Snyder J.A., Lipton J.W., Carvey P.M. Progressive dopamine neuron loss following supra-nigral lipopolysaccharide (LPS) infusion into rats exposed to LPS prenatally. Exp. Neurol. 2006, 199:499-512.
33. Liu M., Hunter R., Nguyen X.V., Kim H.C., Bing G. Microsomal epoxide hydrolase deletion enhances tyrosine hydroxylase phosphorylation in mice after MPTP treatment. J. Neurosci. Res. 2008, 86:2792-2801.
34. Liu M., Choi D.Y., Hunter R.L., Pandya J.D., Cass W.A., Sullivan P.G., Kim H.C., Gash D.M., Bing G. Trichloroethylene induces dopaminergic neurodegeneration in Fisher 344 rats. J. Neurochem. 2010, 112:773-783.
35. Mouton P.R. Principles and practices of unbiased stereology 2002, The Johns Hopkins University Press, Baltimore.
36. Nakamura K., Bindokas V.P., Marks J.D., Wright D.A., Frim D.M., Miller R.J., Kang U.J. The selective toxicity of 1-methyl-4-phenylpyridinium to dopaminergic neurons: the role of mitochondrial complex I and reactive oxygen species revisited. Mol. Pharmacol. 2000, 58:271-278.
37. Naoi M., Maruyama W. Cell death of dopamine neurons in aging and Parkinson's disease. Mech. Ageing Dev. 1999, 111:175-188.
38. Nayernouri T. Posttraumatic parkinsonism. Surg. Neurol. 1985, 24:263-264.
39. Nilsson G.E. Surviving anoxia with the brain turned on. News Physiol. Sci. 2001, 16:217-221.
40. Nuytemans K., Theuns J., Cruts M., Van Broeckhoven C. Genetic etiology of Parkinson disease associated with mutations in the SNCA, PARK2, PINK1, PARK7, and LRRK2 genes: a mutation update. Hum. Mutat. 2010, 31:763-780.
41. The rat nervous system 2004, Elsevier Academic Press, Sydney. G. Paxinos (Ed.).
42. Paxinos G., Watson C. The rat brain in stereotaxic coordinates 1998, Academic Press, Sydney.
43. Ramsay R.R., Salach J.I., Singer T.P. Uptake of the neurotoxin 1-methyl-4-phenylpyridine (MPP+) by mitochondria and its relation to the inhibition of the mitochondrial oxidation of NAD+-linked substrates by MPP+. Biochem. Biophys. Res. Commun. 1986, 134:743-748.
44. Riederer P., Foley P., Bringmann G., Feineis D., Bruckner R., Gerlach M. Biochemical and pharmacological characterization of 1-trichloromethyl-1,2,3,4-tetrahydro-beta-carboline: a biologically relevant neurotoxin?. Eur. J. Pharmacol. 2002, 442:1-16.
45. Sauerbeck A., Pandya J., Singh I., Bittman K., Readnower R., Bing G., Sullivan P. Analysis of regional brain mitochondrial bioenergetics and susceptibility to mitochondrial inhibition utilizing a microplate based system. J. Neurosci. Methods 2011, 198:36-43.
46. Schapira A.H., Cooper J.M., Dexter D., Clark J.B., Jenner P., Marsden C.D. Mitochondrial complex I deficiency in Parkinson's disease. J. Neurochem. 1990, 54:823-827.
47. Semchuk K.M., Love E.J., Lee R.G. Parkinson's disease: a test of the multifactorial etiologic hypothesis. Neurology 1993, 43:1173-1180.
48. Sherer T.B., Betarbet R., Testa C.M., Seo B.B., Richardson J.R., Kim J.H., Miller G.W., Yagi T., Matsuno-Yagi A., Greenamyre J.T. Mechanism of toxicity in rotenone models of Parkinson's disease. J. Neurosci. 2003, 23:10756-10764.
49. Shin S.S., Bray E.R., Zhang C.Q., Dixon C.E. Traumatic brain injury reduces striatal tyrosine hydroxylase activity and potassium-evoked dopamine release in rats. Brain Res. 2011, 1369:208-215.
50. Singh I.N., Sullivan P.G., Deng Y., Mbye L.H., Hall E.D. Time course of post-traumatic mitochondrial oxidative damage and dysfunction in a mouse model of focal traumatic brain injury: implications for neuroprotective therapy. J. Cereb. Blood Flow Metab. 2006, 26:1407-1418.
51. Stern M.B. Head trauma as a risk factor for Parkinson's disease. Mov. Disord. 1991, 6:95-97.
52. Sullivan P.G., Keller J.N., Mattson M.P., Scheff S.W. Traumatic brain injury alters synaptic homeostasis: implications for impaired mitochondrial and transport function. J. Neurotrauma 1998, 15:789-798.
53. Sullivan P.G., Thompson M.B., Scheff S.W. Cyclosporin A attenuates acute mitochondrial dysfunction following traumatic brain injury. Exp. Neurol. 1999, 160:226-234.
54. Sullivan P.G., Thompson M., Scheff S.W. Continuous infusion of cyclosporin A postinjury significantly ameliorates cortical damage following traumatic brain injury. Exp. Neurol. 2000, 161:631-637.
55. Sullivan P.G., Keller J.N., Bussen W.L., Scheff S.W. Cytochrome c release and caspase activation after traumatic brain injury. Brain Res. 2002, 949:88-96.
56. Sullivan P.G., Dube C., Dorenbos K., Steward O., Baram T.Z. Mitochondrial uncoupling protein-2 protects the immature brain from excitotoxic neuronal death. Ann. Neurol. 2003, 53:711-717.
57. Taylor C.A., Saint-Hilaire M.H., Cupples L.A., Thomas C.A., Burchard A.E., Feldman R.G., Myers R.H. Environmental, medical, and family history risk factors for Parkinson's disease: a New England-based case control study. Am. J. Med. Genet. 1999, 88:742-749.
58. Thiruchelvam M., Brockel B.J., Richfield E.K., Baggs R.B., Cory-Slechta D.A. Potentiated and preferential effects of combined paraquat and maneb on nigrostriatal dopamine systems: environmental risk factors for Parkinson's disease?. Brain Res. 2000, 873:225-234.
59. Thiruchelvam M., Richfield E.K., Baggs R.B., Tank A.W., Cory-Slechta D.A. The nigrostriatal dopaminergic system as a preferential target of repeated exposures to combined paraquat and maneb: implications for Parkinson's disease. J. Neurosci. 2000, 20:9207-9214.
60. Veldman B.A., Wijn A.M., Knoers N., Praamstra P., Horstink M.W. Genetic and environmental risk factors in Parkinson's disease. Clin. Neurol. Neurosurg. 1998, 100:15-26.
61. Vyas I., Heikkila R.E., Nicklas W.J. Studies on the neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: inhibition of NAD-linked substrate oxidation by its metabolite, 1-methyl-4-phenylpyridinium. J. Neurochem. 1986, 46:1501-1507.
62. Wagner A.K., Sokoloski J.E., Ren D., Chen X., Khan A.S., Zafonte R.D., Michael A.C., Dixon C.E. Controlled cortical impact injury affects dopaminergic transmission in the rat striatum. J. Neurochem. 2005, 95:457-465.